IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9745294 B1

PDFFull Text
Date of Patent:
Aug. 29, 2017

Filed:

Dec. 16, 2014

2-acylaminopropoanol-type glucosylceramide synthase inhibitors

Applicant:

Genzyme Corporation, Cambridge, MA (US);

Inventors:

Craig Siegel, Woburn, MA (US);

Cecilia M. Bastos, South Grafton, MA (US);

David J. Harris, Lexington, MA (US);

Angeles Dios, Ashland, MA (US);

Edward Lee, Sudbury, MA (US);

Richard Silva, Needham, MA (US);

Lisa M. Cuff, Leominster, MA (US);

Mikaela Levine, Swampscott, MA (US);

Cassandra A. Celatka, Hull, MA (US);

Frederic Vinick, Cambridge, MA (US);

Thomas H. Jozefiak, Belmont, MA (US);

Yibin Xiang, Acton, MA (US);

John Kane, Maynard, MA (US);

Junkai Liao, Andover, MA (US);

Assignee:

Genzyme Corporation, Cambridge, MA (US);

Attorney:

Hamilton, Brook, Smith & Reynolds, P.C.

Primary Examiner:

Samantha Shterengarts

Int. Cl.
CPC ...
A61K 31/42 (2006.01); A61K 31/4245 (2006.01); A61K 31/427 (2006.01); A61K 31/428 (2006.01); A61K 31/4025 (2006.01); A61K 31/40 (2006.01); C07D 417/14 (2006.01); C07D 295/125 (2006.01); C07D 319/18 (2006.01); C07D 405/06 (2006.01); C07D 405/12 (2006.01); C07D 407/12 (2006.01); C07D 409/12 (2006.01); C07D 409/14 (2006.01); C07D 411/12 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 405/14 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); C07D 295/125 (2013.01); C07D 319/18 (2013.01); C07D 405/06 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 407/12 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 411/12 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01);
Abstract

A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Find Patent Forward Citations

Loading…